Evidence map›Paper›PMID 32493336›Full record

ArticleDiagnostic pathology2020

Variation of PD-L1 expression in locally advanced cervical cancer following neoadjuvant chemotherapy.

Yun Liang, Minghua Yu, Caiyun Zhou, Xiaojun Zhu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diagnostic pathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Cervical Cancer Immunotherapy: Facts and Hopes.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Yun LiangDepartment of Surgical Pathology, the Affiliated Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, 310006, Zhejiang Province, China. liangy@zju.edu.cn.
Minghua YuDepartment of Surgical Pathology, the Affiliated Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, 310006, Zhejiang Province, China.
Caiyun ZhouDepartment of Surgical Pathology, the Affiliated Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, 310006, Zhejiang Province, China.
Xiaojun ZhuDepartment of Gynaecology and Obstetrics, the Affiliated Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, 310006, Zhejiang Province, China.
Women's Hospital, School of Medicine, Zhejiang University · CN

Funding

Zhejiang Provincial Natural Science Foundation of China LY20H160029
6 · The paper itself

Abstract

backgroundHigh Programmed death ligand 1 (PD-L1) expression are thought to be necessary to PD-1/PD-L1 axis blockades in many tumors. The aim of the study was to explore the variation of PD-L1 expression after neoadjuvant chemotherapy (NAC) in cervical squamous cell carcinoma (SCC) and its clinical implications.

methodsA total of 142 paired SCC specimens before and after platinum-based NAC were obtained from cervical cancer patients. The expression of PD-L1 and CD3+, CD4+, CD8+ tumor infiltrating lymphocytes (TILs) was detected by immunohistochemistry and the association between TILs, chemotherapy response, clinical outcome and PD-L1 expression was evaluated.

resultsThe fraction of patients with high PD-L1 expression was significantly increased from 32.4 to 46.5% after NAC (χ2 = 5.897, p = 0.015), while the increase of CD3+, CD4+, CD8+ TILs was not significant. High PD-L1 expression was not associated with CD3+, CD4+, CD8+ TILs before NAC, however CD8+ TILs infiltration was positively associated with high PD-L1 expression after NAC (r = 0.205, p = 0.014). The decreased PD-L1 expression was more observed in patients with clinical response to NAC (χ2 = 6.890, p = 0.009). A longer DFS was seen in patients with decreased PD-L1 expression than those with elevated or stable PD-L1 expression (p = 0.048, 95% CI: 0.091-0.987), while the difference was not significant in multivariate analysis (p = 0.113, 95% CI: 0.108-1.266).

conclusionsCisplatin based chemotherapy can increase PD-L1 expression in cervical cancer. The increased PD-L1 expression and a lymphocyte predominant microenvironment after chemotherapy provide a rational for use of PD-1/PD-L1 axis-inhibitor in the neoadjuvant setting.

Indexed as

AdultAgedAntineoplastic Combined Chemotherapy ProtocolsB7-H1 AntigenBiomarkers, TumorCarcinoma, Squamous CellChemotherapy, AdjuvantCisplatinFemaleHumansLymphocytes, Tumor-InfiltratingMiddle AgedNeoadjuvant TherapyPaclitaxelRetrospective StudiesTumor MicroenvironmentB7-H1 AntigenBiomarkers, TumorCD274 protein, humanCisplatinPaclitaxelCervixNeoadjuvant chemotherapyPD-L1Squamous cell carcinomaTumor infiltrating lymphocytes

Identifiers

PMID32493336
PMCPMC7271386
OpenAlexW3031405194

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.